A nonsense mutation results in a premature stop signal in the messenger RNA (mRNA), which stops the ribosome before it completes translating the protein. Our nonsense readthrough technology identifies small molecules that increase readthrough at these premature stop signals to enable the production of full-length proteins. Using this technology, we identified ataluren for the treatment of nonsense mutation genetic disorders. In addition to increasing readthrough, we are also focused on identifying small molecules that stabilize nonsense-containing mRNAs that can enhance the effect of a compound like ataluren that acts through the nonsense readthrough mechanism.

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue